| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| DAROLUTAMIDE (has an active metabolite)
| DAROLUTAMIDE | ANTINEOPLASTIC | ORAL | Cmax 12 MICROMOLAR Tmax 4 HOUR F 30 PERCENT VD 119 LITER PPB 92 PERCENT Cl 6.96 LITER / HOUR HT 20 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN AQUEOUS MEDIUM | ANDROGEN RECEPTOR (AR) | Androgen receptor UNIPROT P10275 AR more at DrugCentral | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| M DAROLUTAMIDE (is an active metabolite)
| DAROLUTAMIDE | ANTINEOPLASTIC | - | PPB 99.8 PERCENT HT 20 HOUR | ANDROGEN RECEPTOR (AR) | Androgen receptor UNIPROT P10275 AR more at DrugCentral | EMA | |||
